Schedule 13G ownership disclosure

BridgeBio Oncology Therapeutics Inc

COMMON STOCK · CUSIP: 107924102

Event date: 2025-09-30

Filing-level shares
885,042
Percent of class
1.1%
  • T. Rowe Price Associates, Inc.

    Shares: 885,042 · Class: 1.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000080255-25-000848
Form type
SCHEDULE 13G
Filer
BridgeBio Pharma, Inc.
CIK
CIK 1743881
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub